Abstract
In recent decades, there has been an exponential growth in both the number and range of catheter-based interventions for adult congenital and structural heart disease. In this article, we discuss the rationale for the ongoing development of minimally invasive multidisciplinary interventions; the required training elements necessary to achieve expertise in the field; the cardiac team needed to best perform these interventions; and the currently available and up and coming technologies for performing transcatheter valve therapies.
Financial & competing interests disclosure
E Horlick has served as a consultant for Edwards Life Sciences, Medtronic, AGA-ST Jude and Biosense Webster. He has served on the speaker‘s bureau for Boehringer and BMS. M Osten has received consulting fees from St Jude and Medtronic. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.